Optimised formula of Fufang Biejia Ruangan tablets alleviates renal fibrosis by suppressing matrix-stiffness–induced fibroblast activation via inhibition of integrin αVβ1 binding
FFBJ-COF was identified as the core bioactive fraction of FFBJ. FFBJ-COF exerts anti-fibrotic effects by inhibiting integrin αVβ1 binding, thereby suppressing the FAK/RhoA/MRTF-A signalling and disrupting the positive feedback loop between ECM stiffness and fibrosis. These findings highlight the potential of FFBJ as a novel therapeutic agent for renal fibrosis.
Authors
- Zijie Zhang (ORCID: https://orcid.org/0009-0005-4410-5925)
- Xiting Wang (ORCID: https://orcid.org/0000-0002-1846-1118)
- Bing Xu (ORCID: https://orcid.org/0000-0001-7720-6363)
- Tong Zhang (ORCID: https://orcid.org/0000-0002-0437-1541)
- Lanwei Zhang (ORCID: https://orcid.org/0000-0003-3459-2975)
- Fang Zhang (ORCID: https://orcid.org/0000-0001-5323-6728)
- Yu Li (ORCID: https://orcid.org/0000-0002-9077-9294)
- Kai Wang (ORCID: https://orcid.org/0000-0003-3317-3509)
- Shuangshuang He (ORCID: https://orcid.org/0000-0002-4402-1642)
- Yuanrong Wang
Institutions
- Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Ethnopharmacology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1016/j.jep.2025.120614
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00